Spenser E. January, Keith A. Fester, Jesus E. Escamilla, Marlene Cano
{"title":"GLP-1和GLP-1/GIP受体激动剂对肺移植术后减重对肺移植功能的影响","authors":"Spenser E. January, Keith A. Fester, Jesus E. Escamilla, Marlene Cano","doi":"10.1111/ctr.70246","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GLP-1/glucose dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) use is becoming increasingly common, but there are little data on their use after lung transplantation. Furthermore, obesity is a known cause of lung function decline after lung transplant, but whether weight loss experienced while on these medications leads to improved lung allograft function has not been investigated.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This single-center retrospective study assessed the use of GLP-1 or GLP-1/GIP RA therapy in patients after lung transplantation. The primary objective was to determine if weight loss is associated with improved lung function. Secondary endpoints included changes in hemoglobin A1c and incidence of adverse effects. A subgroup analysis was performed on only those who lost the median or greater percent of body weight, and a sensitivity analysis was performed to assess if other variables impacting lung function significantly contributed to the endpoints.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 81 lung transplant recipients who received GLP-1 or GLP-1/GIP RA therapy; the average duration of use was 1.4 years. There was significant weight loss and improvement in hemoglobin A1c, but there was no association found between weight loss and improvement in FEV1 or FVC. Side effects were common and led to discontinuation of the medication in 18.5% of patients, but serious side effects were rare.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Use of GLP-1 or GLP-1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c, but this did not lead to improved lung allograft function.</p>\n </section>\n \n <section>\n \n <h3> Summary</h3>\n \n <div>\n <ul>\n \n <li>In this article examining the use of GLP-1 and GLP-1/GIP RA after lung transplantation, there was no significant association between weight loss and an increase in lung allograft function, although approximately half of the patients experienced a rise in FEV<sub>1</sub> and FVC while on therapy.</li>\n \n <li>This study included both a subgroup and a sensitivity analysis to assess if significant weight gain was needed to improve lung function and to assess the impact of other variables on lung function.</li>\n \n <li>Patients in this study experienced significant improvement in weight and hemoglobin A1c. Side effects were common, but serious side effects were rare.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 8","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of GLP-1 and GLP-1/GIP Receptor Agonist Weight Loss Post-Lung Transplant on Lung Allograft Function\",\"authors\":\"Spenser E. January, Keith A. Fester, Jesus E. Escamilla, Marlene Cano\",\"doi\":\"10.1111/ctr.70246\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GLP-1/glucose dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) use is becoming increasingly common, but there are little data on their use after lung transplantation. Furthermore, obesity is a known cause of lung function decline after lung transplant, but whether weight loss experienced while on these medications leads to improved lung allograft function has not been investigated.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This single-center retrospective study assessed the use of GLP-1 or GLP-1/GIP RA therapy in patients after lung transplantation. The primary objective was to determine if weight loss is associated with improved lung function. Secondary endpoints included changes in hemoglobin A1c and incidence of adverse effects. A subgroup analysis was performed on only those who lost the median or greater percent of body weight, and a sensitivity analysis was performed to assess if other variables impacting lung function significantly contributed to the endpoints.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>There were 81 lung transplant recipients who received GLP-1 or GLP-1/GIP RA therapy; the average duration of use was 1.4 years. There was significant weight loss and improvement in hemoglobin A1c, but there was no association found between weight loss and improvement in FEV1 or FVC. Side effects were common and led to discontinuation of the medication in 18.5% of patients, but serious side effects were rare.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Use of GLP-1 or GLP-1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c, but this did not lead to improved lung allograft function.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Summary</h3>\\n \\n <div>\\n <ul>\\n \\n <li>In this article examining the use of GLP-1 and GLP-1/GIP RA after lung transplantation, there was no significant association between weight loss and an increase in lung allograft function, although approximately half of the patients experienced a rise in FEV<sub>1</sub> and FVC while on therapy.</li>\\n \\n <li>This study included both a subgroup and a sensitivity analysis to assess if significant weight gain was needed to improve lung function and to assess the impact of other variables on lung function.</li>\\n \\n <li>Patients in this study experienced significant improvement in weight and hemoglobin A1c. Side effects were common, but serious side effects were rare.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":\"39 8\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70246\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70246","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Impact of GLP-1 and GLP-1/GIP Receptor Agonist Weight Loss Post-Lung Transplant on Lung Allograft Function
Introduction
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GLP-1/glucose dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) use is becoming increasingly common, but there are little data on their use after lung transplantation. Furthermore, obesity is a known cause of lung function decline after lung transplant, but whether weight loss experienced while on these medications leads to improved lung allograft function has not been investigated.
Methods
This single-center retrospective study assessed the use of GLP-1 or GLP-1/GIP RA therapy in patients after lung transplantation. The primary objective was to determine if weight loss is associated with improved lung function. Secondary endpoints included changes in hemoglobin A1c and incidence of adverse effects. A subgroup analysis was performed on only those who lost the median or greater percent of body weight, and a sensitivity analysis was performed to assess if other variables impacting lung function significantly contributed to the endpoints.
Results
There were 81 lung transplant recipients who received GLP-1 or GLP-1/GIP RA therapy; the average duration of use was 1.4 years. There was significant weight loss and improvement in hemoglobin A1c, but there was no association found between weight loss and improvement in FEV1 or FVC. Side effects were common and led to discontinuation of the medication in 18.5% of patients, but serious side effects were rare.
Conclusion
Use of GLP-1 or GLP-1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c, but this did not lead to improved lung allograft function.
Summary
In this article examining the use of GLP-1 and GLP-1/GIP RA after lung transplantation, there was no significant association between weight loss and an increase in lung allograft function, although approximately half of the patients experienced a rise in FEV1 and FVC while on therapy.
This study included both a subgroup and a sensitivity analysis to assess if significant weight gain was needed to improve lung function and to assess the impact of other variables on lung function.
Patients in this study experienced significant improvement in weight and hemoglobin A1c. Side effects were common, but serious side effects were rare.
期刊介绍：
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
